Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe

Esther Kissling (1) , Marc Rondy (2) , I-Move Study (3, 4, 5, 6, 7, 8, 9, 10)

1 EpiConcept [Paris]
2 BPH - Bordeaux population health
3 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
4 CNRS-UMR3569 - Virologie
5 CIRI - Centre International de Recherche en Infectiologie
6 CNR - laboratoire coordonnateur - Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris]
7 F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC)
8 Hôpital Cochin [AP-HP]
9 GMV-ARN (UMR_3569 / U-Pasteur_2) - Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses
10 CNR - laboratoire associé - Centre National de Référence des Virus des Infections Respiratoires (dont la Grippe) [Lyon]

We measured early 2016/17 season influenza vaccine effectiveness (IVE) against influenza A(H3N2) in Europe using multicentre case control studies at primary care and hospital levels. IVE at primary care level was 44.1%, 46.9% and 23.4% among 0–14, 15–64 and ≥ 65 year-olds, and 25.7% in the influenza vaccination target group. At hospital level, IVE was 2.5%, 7.9% and 2.4% among ≥ 65, 65–79 and ≥ 80 year-olds. As in previous seasons, we observed suboptimal IVE against influenza A(H3N2).

Mots clés: ILI; SARI; immunisation; influenza; influenza like illness; severe acute respiratory infection; vaccine effectiveness; vaccines

Domaines: Santé publique et épidémiologie; Vaccinologie; Maladies infectieuses; Pneumologie et système respiratoire

Esther Kissling, Marc Rondy, I-Move Study. Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe. Eurosurveillance, 2017, 22 (7), pp.30464. ⟨10.2807/1560-7917.ES.2017.22.7.30464⟩. ⟨hal-03954015⟩